Navigation Links
Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Date:2/28/2011

T-cell levels and no detectable viral load on long-term HAART.  The trial has three dosing cohorts.  Subjects will remain on their existing antiviral therapy while receiving treatment with SB-728-T. A fourth cohort, of up to four subjects who have failed HAART and have measureable viral loads, was recently added to the study.  No data from subjects in the last two cohorts of this study were reported in today's CROI presentation. The primary objective of the study is to evaluate the safety and tolerability of SB-728-T. In addition to safety monitoring, data are being collected on the expansion, trafficking and persistence of SB-728-T, total CD4+ T-cell counts, CD4:CD8 T-cell ratios and viral load.

Dr. June has no financial relationship with Sangamo BioSciences, Inc.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1 / 2 clinical trial and two ongoing Phase 1 clinical trials to evaluate the safety and efficacy for the treatment of HIV/AIDS as well as a Phase 1 trial for the treatment for recurrent glioblastoma multiforme. Other therapeutic programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 UBM Medica ... – a new online community and information resource for ... manage and treat their patients with neurological disorders ... with an aging population, necessitates greater access to dedicated ...  Key statistics on neurological conditions include: , ...
(Date:7/23/2014)... , July 23, 2014 Research and ... Electrocardiograph (ECG) Market by Product, End-user & by Lead ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... segmented into three major segments, namely, holter monitor, resting, ... was valued at $3,683 million in 2013 and is ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid Services ... Improvement Organization (QIN-QIO) contract to a partnership led by ... August 1, WVMI will launch Quality Insights Quality Innovation ... Pennsylvania , Delaware , ... Network will engage providers and the community in multiple, ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... Celebrating a decade of philanthropy in 2014, The ... of $1,070,000 in grants to 20 New Jersey non-profit ... Foundation’s 1,000th grant. , “The Horizon Foundation for New ... community-based organizations that are working to improve public health ... State,” said Robert A. Marino, Horizon Blue Cross Blue ...
(Date:7/23/2014)... Painful or itchy skin lesions could be a warning ... have multiple lesions that are suspicious looking, and those ... for non-melanoma skin cancers," study author Dr. Gil Yosipovitch, ... said in a Temple University Health System news release. ... patients who were confirmed to have skin cancer lesions ...
(Date:7/23/2014)... University in Shaanxi province, and the University of California, ... the groundwork for establishing the Sino-U.S. Joint Research Center ... was held in the city of Yingchuan, China, during ... of Agriculture and China,s Ministry of Science and Technology. ... Davis and for our World Food Center and serves ...
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2
... Case Western Reserve University School of Medicine has developed ... lymphoblastic leukemia (ALL). ALL is the most common type ... each year in the United States. The findings provide ... development of "theranostic" agents-- a treatment platform that combines ...
... HealthDay Reporter , TUESDAY, March 6 (HealthDay News) ... stave off hot flashes, night sweats and other symptoms of ... down the road, a news study says. Hormone replacement ... government-run trial, the U.S. Women,s Health Initiative, was stopped early ...
... assistant professor of computer science and robotics engineering at ... CAREER Award from the National Science Foundation (NSF) to ... purpose robots that can work effectively and productively alongside ... WPI faculty members to receive the CAREER Award, the ...
... Mar 07, 2012-200 million teenagers suffer from depression ... results have led to increased controversy surrounding the ... on the latest research findings on antidepressant medications ... by Journal of Child and Adolescent Psychopharmacology (http://www.liebertpub.com/cap), ...
... at the University of Warwick have used state-of-the-art nuclear ... how pharmaceutical molecules pack together in the solid state. ... NMR magnets, housed at the University of Warwick, to ... and GlaxoSmithKline. The analytical methods look directly ...
... FRANCISCO March 6, 2012 A new paradigm to ... treatment advances that may ultimately vanquish the disease known as ... Ophthalmology , the journal of the American Academy of ... glaucoma solely as an eye disease. Instead, they view it ...
Cached Medicine News:Health News:Researchers develop first 'theranostic' treatment for acute lymphoblastic leukemia (ALL) 2Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 2Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 3Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 4Health News:WPI's Sonia Chernova wins NSF CAREER award for work aimed at creating 'everyday' robots 2Health News:More effective treatments urgently needed for adolescent depression 2Health News:New research characterizes glaucoma as neurologic disorder rather than eye disease 2
... using patented, innovative technology, measures a complete ... only 5 minutes from a simple fingerstick. ... get immediate liver function results. The scope ... only advantage to healthcare providers. The physician, ...
The Strep A Rapid Test Strip is a rapid chromatographic,immunoassay for the qualitative detection of Strep A antigen,from throat swab specimens to aid in the diagnosis of Group A,Streptococcal ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
Medicine Products: